Randomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial

BACKGROUND: Docetaxel administered 3-weekly with cisplatin and 5-fluorouracil leads to better survival than does standard therapy in patients with oesophagogastric cancer, but leads to high rates of haematological toxicity. Weekly docetaxel is associated with less haematological toxicity. This rando...

Descripción completa

Detalles Bibliográficos
Autores principales: Tebbutt, N C, Cummins, M M, Sourjina, T, Strickland, A, Van Hazel, G, Ganju, V, Gibbs, D, Stockler, M, Gebski, V, Zalcberg, J
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2010
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2822950/
https://www.ncbi.nlm.nih.gov/pubmed/20068567
http://dx.doi.org/10.1038/sj.bjc.6605522

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2822950/
https://www.ncbi.nlm.nih.gov/pubmed/20068567
http://dx.doi.org/10.1038/sj.bjc.6605522

Ejemplares similares